VIP + PEG-MGF Research Data

Natural Aminos Research Stack or Formula of the Day

VIP + PEG-MGF

Vasoactive/Immunoregulatory Signaling + Experimental IGF-1Ec/Muscle-Repair Research Spotlight

Compound Identity & Current Evidence Context

VIP is vasoactive intestinal peptide, a 28-amino-acid endogenous neuropeptide with broad activity through VPAC1 and VPAC2 receptors. Synthetic human VIP is commonly called aviptadil. VIP increases intracellular cAMP and has vasodilatory, bronchodilatory, epithelial, surfactant-related, and immunoregulatory effects. Human research includes pulmonary hypertension, sarcoidosis, acute respiratory failure, and COVID-19 lung injury, but aviptadil does not have an FDA-approved therapeutic indication. FDA has granted orphan designation for sarcoidosis without orphan approval, and the European Union granted a new orphan designation for aviptadil in acute respiratory distress syndrome on February 23, 2026; orphan designation is not marketing authorization.

PEG-MGF means pegylated mechano growth factor, generally marketed as a PEGylated version of a synthetic peptide derived from the E-domain of the IGF-1Ec splice variant. The terminology is scientifically difficult: MGF can refer to the IGF-1Ec transcript/pro-IGF-1 isoform, to a proposed C-terminal E-domain peptide, or to synthetic peptides modeled on that sequence. PEG-MGF adds polyethylene glycol to prolong persistence, but no peer-reviewed human clinical study has established its pharmacokinetics, safety, route, or efficacy.

A 2026 peer-reviewed review of performance-enhancing peptides specifically classified PEG-MGF as having no peer-reviewed human studies and no established human administration route. This makes PEG-MGF fundamentally different from VIP: VIP has direct controlled and uncontrolled human clinical exposure, whereas PEG-MGF is supported by cell and animal literature plus extrapolation from IGF-1 biology.

No peer-reviewed human, animal, or cell study was identified that administered VIP/aviptadil and PEG-MGF together. The stack therefore has no direct evidence of synergy, safety, pharmacokinetic interaction, or improved outcomes.

Benefits

VIP / Aviptadil

VIP has direct human pulmonary vascular activity. In a 20-patient study performed during right-heart catheterization, a single inhaled dose of aviptadil produced modest, short-lived selective pulmonary vasodilation, improved stroke volume and mixed venous oxygen saturation, and did not significantly reduce systemic blood pressure. Six of twenty participants had more than a 20% reduction in pulmonary vascular resistance. The study established acute physiology, not long-term disease modification.

VIP also has human immunoregulatory evidence. In an open Phase II study of 20 patients with active sarcoidosis, four weeks of inhaled VIP reduced tumor-necrosis-factor-alpha production from bronchoalveolar-lavage cells and increased regulatory T-cell populations. Treatment was reported as safe and well tolerated in that small study. These findings support immune modulation in the lung but do not establish broad anti-inflammatory efficacy.

COVID-19 and acute respiratory failure produced mixed results. A 196-patient randomized trial of intravenous aviptadil did not meet its prespecified primary endpoint of being alive and free from respiratory failure at day 60. The larger NIH-sponsored TESICO trial was stopped for futility; the day-90 ordinal outcome was not improved and mortality was similar between aviptadil and placebo.

A later 2025 multicenter randomized inhaled-aviptadil study in 80 hospitalized COVID-19 patients reported a shorter average time to discharge, improved day-28 CT lung-damage scores, and no treatment withdrawals for adverse effects. This positive smaller trial does not erase the negative intravenous trials; it suggests that route, disease timing, population, and endpoint may materially affect the response.

VIP biology is context dependent. Its immunoregulatory actions may be useful when excessive inflammation is harmful, but immune suppression can theoretically be undesirable in uncontrolled infection or impaired host defense. Its vasodilatory activity can also produce hemodynamic effects, particularly with systemic exposure.

PEG-MGF

PEG-MGF is promoted as a longer-acting version of MGF intended to support local muscle repair, satellite-cell activity, and tissue regeneration. The underlying biological rationale comes from research showing that the IGF-1Ec/MGF transcript is induced after mechanical loading or muscle injury and is associated with repair and adaptation.

Some experimental studies of synthetic MGF E-domain peptides report effects on muscle progenitor cells. A 2011 study using primary human muscle progenitor cells found that a 24-amino-acid MGF E peptide increased proliferative lifespan and fusion potential in neonatal and young-adult cultures, although responses were weaker in older-adult cells.

However, reproducibility is a major problem. In 2014, investigators from two pharmaceutical research groups tested native and stabilized MGF peptides in C2C12 cells, primary human skeletal-muscle myoblasts, and primary mouse muscle stem cells. They found no significant proliferation, differentiation, or ERK-signaling effect from the MGF peptide while mature IGF-1 produced the expected responses. The authors concluded that their findings called the proposed physiological role of the synthetic MGF peptide into question.

The identity problem is equally important. A major review noted that although an IGF-1 splice transcript called MGF is clearly regulated after injury, an analogous free E-domain peptide product has not been definitively isolated from cells, conditioned media, animal tissues, or biological fluids. Therefore, synthetic MGF E peptide and PEG-MGF should not automatically be treated as the endogenous IGF-1Ec system.

There is also a theoretical proliferative concern. IGF-1Ec/MGF expression is elevated in several tumor contexts. A 2010 prostate-cancer study found preferential IGF-1Ec expression in cancer tissue and reported that synthetic MGF E peptide stimulated proliferation of prostate-cancer cells through ERK signaling. This does not prove PEG-MGF causes cancer, but it weakens claims that experimental proliferative signaling is inherently benign.

What the Formulas Are Studied For

VIP / Aviptadil Research Areas

• Pulmonary vascular resistance and pulmonary hypertension physiology.

• Sarcoidosis and lung immunoregulation.

• ARDS and acute hypoxemic respiratory failure.

• COVID-19 lung injury and recovery.

• Airway epithelial and surfactant biology.

• VPAC1/VPAC2 signaling, cAMP/PKA pathways, and immune tolerance.

• Vasodilation, bronchodilation, and pulmonary oxygenation.

PEG-MGF Research Areas

• Mechanical-load and injury-associated IGF-1Ec/MGF biology.

• Skeletal-muscle satellite-cell activation and regeneration hypotheses.

• Muscle progenitor-cell proliferation and differentiation in vitro.

• Age-related decline in local muscle growth-factor responses.

• Neuroprotection and tissue-repair models linked to IGF-1 splice variants.

• PEGylation as a proposed strategy to extend peptide persistence.

• No established human therapeutic indication or peer-reviewed clinical efficacy dataset.

Published Research - Worldwide Evidence Review

VIP / Aviptadil - Europe, United States and Multicenter Respiratory Research

European pulmonary-hypertension research established that inhaled VIP has a selective but modest acute pulmonary vasodilatory effect. The 20-patient catheterization study found reduced pulmonary vascular resistance in a subset and improved right-ventricular workload without meaningful systemic hypotension.

German investigators then studied inhaled VIP in 20 patients with active sarcoidosis. The study documented reduced TNF-alpha production and increased regulatory T-cell activity in bronchoalveolar lavage samples. This is one of the clearest human demonstrations that VIP can modify immune-cell behavior in the lung.

The U.S. COVID development program was less successful. In the 196-patient randomized intravenous study, the primary endpoint did not reach statistical significance. TESICO, conducted at 28 U.S. sites, was stopped for futility; the primary day-90 outcome and mortality were not improved by aviptadil.

A 2025 Turkish multicenter randomized inhaled study produced a more favorable signal in 80 patients, including shorter hospitalization and improved radiologic recovery. In February 2026, the European Union granted aviptadil orphan designation for ARDS, indicating continuing development interest but not proof of efficacy or authorization.

PEG-MGF - United Kingdom, France, Switzerland and Experimental Muscle Biology

The MGF concept emerged from British muscle-biochemistry research showing that mechanically loaded or injured muscle alters IGF-1 splicing and increases an IGF-1Ec/MGF transcript. Human resistance-training studies have also documented changes in MGF/IGF-1Ec gene expression after exercise. Those studies measure endogenous transcript regulation; they do not test injected PEG-MGF.

French investigators reported in 2011 that a synthetic 24-amino-acid MGF E peptide affected primary human muscle progenitor-cell proliferation and fusion. In contrast, a 2014 multinational pharmaceutical study failed to reproduce proliferative or signaling effects from native or stabilized MGF peptide in human and mouse muscle cells. This contradiction remains central to interpretation of the peptide.

A 2026 endocrine review concluded that PEG-MGF has no peer-reviewed human clinical studies and no documented clinical administration route. It emphasized that any performance or regenerative claim remains preclinical and that proliferative risk must be considered in the context of IGF-1Ec/MGF expression in cancer biology.

Direct Research on VIP + PEG-MGF Together

No peer-reviewed human, animal, or cell study was identified that administered VIP/aviptadil and PEG-MGF together as a defined intervention. No registered clinical trial of the pair was identified in the reviewed evidence.

There is also no direct pairwise pharmacokinetic study showing whether VIP-mediated vasodilation or cAMP signaling changes PEG-MGF tissue distribution, and no study showing whether PEG-MGF modifies VIP immune or pulmonary effects. Any proposed interaction is therefore theoretical.

Theory of the Stack - How the Combination Could Work

1. Vascular and Immunoregulatory Signaling - VIP Layer

VIP would provide the vascular, epithelial, and immunoregulatory layer. Through VPAC receptors and cAMP signaling, it could theoretically improve local blood flow, reduce selected pro-inflammatory signals, influence epithelial survival, and modify pulmonary or tissue immune responses.

2. Local Repair/Growth Signaling - PEG-MGF Layer

PEG-MGF would theoretically provide a tissue-repair and muscle-regeneration layer derived from the IGF-1Ec/MGF concept. Its proposed role is to extend exposure to an MGF-like signal after mechanical stress or injury and thereby influence progenitor-cell activity. This remains an experimental hypothesis rather than a clinically demonstrated effect.

3. The Pair Is Mechanistically Complementary Rather Than Redundant

VIP and PEG-MGF do not target the same primary receptor system. VIP primarily signals through VPAC receptors and cAMP, whereas MGF-related biology is linked to IGF-1 splice-variant/tissue-repair pathways and possibly ERK-related signaling. This reduces direct receptor redundancy.

4. Better Perfusion Could Theoretically Support Repair - but Has Not Been Tested

A simple theory is that VIP-mediated vasodilation could improve local oxygen and nutrient delivery while PEG-MGF supports regenerative signaling. No study has demonstrated that aviptadil enhances MGF-driven repair or that perfusion is the limiting factor in any PEG-MGF model.

5. Immunoregulation Could Help or Hinder Repair Depending on Timing

Inflammation is not uniformly harmful. Early inflammatory signaling contributes to debris clearance, immune recruitment, and initiation of tissue repair. VIP-mediated suppression of inflammatory pathways could theoretically protect tissue from excessive inflammation, but excessive or poorly timed suppression could also alter normal healing or antimicrobial defense.

6. PEG-MGF Is the Clinical Bottleneck

The complete stack cannot be considered clinically established because PEG-MGF has no peer-reviewed human efficacy or safety program. Human VIP exposure does not validate the second compound, and combination theory cannot substitute for missing toxicology, pharmacokinetics, and dose-response data.

7. Cancer Biology Is a Material Uncertainty

A proposed regenerative signal that increases proliferation must be evaluated in tissues with dysplasia or malignancy risk. IGF-1Ec/MGF expression and synthetic MGF E-peptide activity have been reported in prostate-cancer models. No evidence establishes that PEGylation removes this theoretical proliferative concern.

8. VIP Is Also Context Dependent

VIP can be anti-inflammatory and vasodilatory, but it is not a universal repair peptide. Large randomized respiratory-failure studies failed to show clear benefit, illustrating that favorable cellular mechanisms may not translate to clinical outcomes even when the compound has direct human exposure.

9. Route and Formulation Matter

VIP evidence differs by inhaled versus intravenous administration. PEG-MGF has no peer-reviewed human route or pharmacokinetic study. A modern experimental stack using subcutaneous or other routes cannot be assumed to reproduce inhaled VIP lung effects or endogenous MGF biology.

10. The Most Coherent Research Question Is Injury/Repair, Not General Performance

A scientifically coherent combination hypothesis would study a defined injury model in which perfusion, inflammatory signaling, and local muscle or tissue repair can all be measured. Generic claims of recovery, strength, anti-aging, or systemic regeneration are much broader than the evidence supports.

Possible Overall Benefit - Theoretical, Not Proven

The most defensible theoretical benefit of VIP + PEG-MGF is coordinated control of the tissue environment during repair: VIP could theoretically reduce excessive inflammatory signaling and improve local vascular/epithelial conditions, while PEG-MGF could theoretically promote local regenerative or progenitor-cell responses.

This theory is biologically complementary but clinically weak because the two components are at very different evidence levels. VIP has demonstrated human pulmonary and immune pharmacology, although major respiratory trials have been mixed or negative. PEG-MGF has no peer-reviewed human clinical evidence and an unresolved identity/reproducibility problem.

No evidence shows that the combination improves muscle recovery, wound healing, pulmonary function, strength, endurance, or tissue regeneration more than either component alone. Any overall benefit must therefore be labeled a hypothesis.

Why More Research Is Needed

• No published study has tested VIP/aviptadil + PEG-MGF together.

• PEG-MGF has no peer-reviewed human clinical studies, established route, pharmacokinetic profile, or efficacy dataset.

• Synthetic MGF E-peptide results are contradictory: some studies report progenitor-cell effects while a pharmaceutical replication study found no effect in human or mouse muscle cells.

• The relationship between endogenous IGF-1Ec/MGF transcripts and a free biologically active MGF E peptide remains scientifically disputed.

• PEGylation may change exposure and tissue distribution, but those effects have not been characterized clinically for PEG-MGF.

• VIP human evidence is indication and route dependent: pulmonary-hemodynamic and sarcoidosis signals are small, and large intravenous COVID respiratory-failure trials were negative.

• The 2025 positive inhaled-aviptadil trial was small and should be independently replicated.

• VIP-mediated immune suppression could be beneficial or harmful depending on infection status, timing, and tissue context.

• IGF-1Ec/MGF expression and synthetic MGF E-peptide proliferative activity in cancer models create a theoretical neoplasia concern requiring dedicated toxicology.

• No study defines whether VIP alters PEG-MGF delivery or whether PEG-MGF alters vascular, immune, or pulmonary responses to VIP.

• Future studies should include VIP-alone, PEG-MGF-alone, combination, and placebo arms with objective measures of perfusion, inflammatory signaling, muscle/tissue regeneration, cell proliferation, and adverse events.

• Any first-in-human PEG-MGF program would require formal dose escalation, pharmacokinetics, immunogenicity, metabolic monitoring, and long-term proliferative safety assessment before a combination trial.

Research Summary

VIP + PEG-MGF is a biologically broad but clinically unvalidated vascular/immunoregulatory-plus-regenerative stack. VIP/aviptadil has direct human pharmacology and small positive pulmonary and immunoregulatory studies, but major randomized intravenous respiratory-failure trials have been negative. A smaller 2025 inhaled study produced a favorable signal, and aviptadil received a new EU orphan designation for ARDS in 2026, but it remains investigational rather than an approved general pulmonary or immune therapy.

PEG-MGF is much less mature. Endogenous IGF-1Ec/MGF transcript biology is well documented after muscle loading and injury, but the existence and function of a separate endogenous MGF E peptide remain debated, experimental synthetic-peptide studies conflict, and no peer-reviewed human PEG-MGF clinical study has established safety or efficacy. The combination has never been directly tested.

Selected Sources

• Leuchte HH, et al. Inhalation of vasoactive intestinal peptide in pulmonary hypertension. Eur Respir J. 2008. PMID: 18978135.

• Prasse A, et al. Inhaled vasoactive intestinal peptide exerts immunoregulatory effects in sarcoidosis. Am J Respir Crit Care Med. 2010. PMID: 20442436. DOI: 10.1164/rccm.200909-1451OC.

• Youssef JG, et al. The Use of IV Vasoactive Intestinal Peptide (Aviptadil) in Patients With Critical COVID-19 Respiratory Failure: Results of a 60-Day Randomized Controlled Trial. Crit Care Med. 2022. PMID: 36044317.

• TESICO investigators. Intravenous aviptadil and remdesivir for COVID-19-associated hypoxaemic respiratory failure: a randomized placebo-controlled trial. Lancet Respir Med. 2023. PMID: 37348524.

• Esendagli D, et al. Inhaled Aviptadil Is a New Hope for Recovery of Lung Damage due to COVID-19. Med Princ Pract. 2025;34(2):191-200. PMID: 39870064. DOI: 10.1159/000543773.

• U.S. Food and Drug Administration. Orphan Drug Designation database: Aviptadil for treatment of sarcoidosis; designated July 23, 2020; not FDA approved for the orphan indication.

• European Medicines Agency. EU/3/26/3200: Aviptadil orphan designation for acute respiratory distress syndrome, designated February 23, 2026. Orphan designation does not constitute marketing authorization.

• Kandalla PK, et al. Mechano Growth Factor E peptide activates human muscle progenitor cells and increases fusion potential at different ages. Mech Ageing Dev. 2011. PMID: 21354439. DOI: 10.1016/j.mad.2011.02.007.

• Fornaro M, et al. Mechano-growth factor peptide has no apparent effect on myoblasts or primary muscle stem cells. Am J Physiol Endocrinol Metab. 2014. PMID: 24253050. DOI: 10.1152/ajpendo.00408.2013.

• Matheny RW Jr, et al. Mechano-growth factor: a putative product of IGF-I gene expression involved in tissue repair and regeneration. Endocr Rev. 2010. PMID: 20130113.

• Armakolas A, et al. Preferential expression of IGF-1Ec (MGF) transcript in cancerous tissues of human prostate and mitogenic activity of MGF E peptide. Prostate. 2010. PMID: 20564425. DOI: 10.1002/pros.21158.

• Dominikowski A, et al. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Front Endocrinol. 2026. PMID: 42395176. PMCID: PMC13322892. DOI: 10.3389/fendo.2026.1822475.

Theory vs. Proof - Verdict

What is supported by evidence: VIP/aviptadil can alter human pulmonary vascular tone and human lung immune-cell behavior; inhaled VIP has small positive clinical studies, while larger intravenous acute-respiratory-failure trials have been negative. Endogenous IGF-1Ec/MGF transcription responds to mechanical loading and injury, and some synthetic MGF E-peptide cell studies report effects on muscle progenitor cells.

What is not proven: that PEG-MGF is equivalent to endogenous IGF-1Ec/MGF biology; that PEG-MGF is safe or effective in humans; that it improves muscle growth, repair, recovery, or performance; that VIP improves tissue repair outside studied contexts; or that VIP and PEG-MGF together are additive, synergistic, or clinically useful.

Verdict - theory vs. proof: the mechanisms are potentially complementary but the evidence is highly asymmetric and the combination is highly speculative. VIP supplies a genuine human vasoactive and immunoregulatory pathway through VPAC/cAMP signaling. PEG-MGF supplies a proposed regenerative/growth pathway derived from controversial and internally inconsistent MGF-peptide literature, with no peer-reviewed human clinical program. The most coherent theory is improved tissue environment plus local repair signaling, but no direct combination evidence supports it, and PEG-MGF introduces unresolved proliferative, identity, pharmacokinetic, and safety questions. Overall, VIP + PEG-MGF is best classified as a biologically plausible but clinically unproven repair hypothesis with moderate human evidence for VIP, preclinical and contradictory evidence for PEG-MGF, and no demonstrated combination benefit.

Research & Educational Use Only !!